Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
// Susanne Lorenz 1,5 , Tale Barøy 1,14 , Jinchang Sun 2,5 , Torfinn Nome 3,10 , Daniel Vodák 1 , Jan-Christian Bryne 1,2 , Anne-Mari Håkelien 1 , Lynnette Fernandez-Cuesta 6,7 , Birte Möhlendick 8 , Harald Rieder 8 , Karoly Szuhai 9 , Olga Zaikova 4 , Terje C. Ahlquist 3,10 , Gard O. S. Thomassen 3,10 , Rolf I. Skotheim 3,10 , Ragnhild A. Lothe 3,10 , Patrick S. Tarpey 11 , Peter Campbell 11 , Adrienne Flanagan 12,13 , Ola Myklebost 1,5,* and Leonardo A. Meza-Zepeda 1,2,5,* 1 Department of Tumor Biology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway 2 Genomics Core Facility, Department of Core Facilities, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway 3 Department of Molecular Oncology, Institute for Cancer research, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway 4 Clinic for Cancer, Surgery and Transplantation, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway 5 Norwegian Cancer Genomics Consortium, Norway 6 Department of Translational Genomics, Center of Integrated Oncology Cologne–Bonn, University of Cologne, Cologne, Germany 7 Genetic Cancer Susceptibility Group, International Agency for Research on Cancer (IARC-WHO), Lyon, France 8 Institute for Human Genetics, University Hospital Düsseldorf, Düsseldorf, Germany 9 Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands 10 Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway 11 Wellcome Trust Sanger Institute, Hinxton, UK 12 Royal National Orthopaedic Hospital, Middlesex, UK 13 UCL Cancer Institute, University College London, London, UK 14 Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway * These authors shared last authorship Correspondence to: Leonardo A. Meza-Zepeda, email: // Keywords : bone cancer, osteosarcomas, gene fusion, trans-splicing, DNA repair Received : July 16, 2015 Accepted : November 15, 2015 Published : December 11, 2015 Abstract In contrast to many other sarcoma subtypes, the chaotic karyotypes of osteosarcoma have precluded the identification of pathognomonic translocations. We here report hundreds of genomic rearrangements in osteosarcoma cell lines, showing clear characteristics of microhomology-mediated break-induced replication (MMBIR) and end-joining repair (MMEJ) mechanisms. However, at RNA level, the majority of the fused transcripts did not correspond to genomic rearrangements, suggesting the involvement of trans-splicing, which was further supported by typical trans-splicing characteristics. By combining genomic and transcriptomic analysis, certain recurrent rearrangements were identified and further validated in patient biopsies, including a PMP22-ELOVL5 gene fusion, genomic structural variations affecting RB1, MTAP/CDKN2A and MDM2 , and, most frequently, rearrangements involving TP53. Most cell lines (7/11) and a large fraction of tumor samples (10/25) showed TP53 rearrangements, in addition to somatic point mutations (6 patient samples, 1 cell line) and MDM2 amplifications (2 patient samples, 2 cell lines). The resulting inactivation of p53 was demonstrated by a deficiency of the radiation-induced DNA damage response. Thus, TP53 rearrangements are the major mechanism of p53 inactivation in osteosarcoma. Together with active MMBIR and MMEJ, this inactivation probably contributes to the exceptional chromosomal instability in these tumors. Although rampant rearrangements appear to be a phenotype of osteosarcomas, we demonstrate that among the huge number of probable passenger rearrangements, specific recurrent, possibly oncogenic, events are present. For the first time the genomic chaos of osteosarcoma is characterized so thoroughly and delivered new insights in mechanisms involved in osteosarcoma development and may contribute to new diagnostic and therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 15×
“In the tumor cohort we identified 5 samples harboring rearrangements in or around the RB1 locus, with 4 samples containing translocations (2 in intron 2, 1 in intron 7, 1 in intron 21) and one sample with a 2.7 Mb deletion covering the whole gene.”
BackgroundInfluentialRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“Two cell lines (MHM, OSA) and two tumor samples harboring wild type p53 showed inactivation of the p53 pathway by MDM2 gene amplification [47].”
BackgroundMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · cited 1×
“On the other hand, focused copy number changes could be identified, among them, frequent deletion of LSAMP [4, 5], and amplification of CDK4 and MDM2 [6], leading to inactivation of RB1 [7] and TP53 [8], respectively.”
BackgroundMassive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Self-citationZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752 · cited 18×
“In the tumor cohort we identified 5 samples harboring rearrangements in or around the RB1 locus, with 4 samples containing translocations (2 in intron 2, 1 in intron 7, 1 in intron 21) and one sample with a 2.7 Mb deletion covering the whole gene.”
BackgroundResultInfluentialSmall-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Self-citation
Cited by
Advancing therapy for osteosarcoma
Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876
Germline and somatic genetics of osteosarcoma — connecting aetiology, biology and therapy
Gianferante, D. M., Mirabello, L., & Savage, S. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.16 · Cited by 477
Osteosarcoma: Molecular Pathogenesis and iPSC Modeling
Lin, Y.-H., Jewell, B. E., Gingold, J., Lu, L., Zhao, R., Wang, L. L., & Lee, D.-F. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.06.004 · Cited by 150
“, TP53–VAV1, TP53–EMR1, TP53–PPRAD, and TP53–KPNA3) resulted in the inactivation of p53 in osteosarcoma, explaining how TP53 gene function can be consistently disrupted in osteosarcoma despite the low observed prevalence of TP53mutations in sporadic osteosarcomas, as shown by traditional mutation analyses [5,7].”
ResultSundara, Y. T., Kostine, M., Cleven, A. H. G., Bovée, J. V. M. G., Schilham, M. W., & Cleton-Jansen, A.-M. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1925-3 · Cited by 111
Aran, V., Devalle, S., Meohas, W., Heringer, M., Cunha Caruso, A., Pinheiro Aguiar, D., Leite Duarte, M. E., & Moura Neto, V. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103340 · Cited by 87
Metadata
- Authors
- Lorenz, S., Barøy, T., Sun, J., Nome, T., Vodák, D., Bryne, J.-C., Håkelien, A.-M., Fernandez-Cuesta, L., Möhlendick, B., Rieder, H., Szuhai, K., Zaikova, O., Ahlquist, T. C., Thomassen, G. O. S., Skotheim, R. I., Lothe, R. A., Tarpey, P. S., Campbell, P., Flanagan, A., Myklebost, O., & Meza-Zepeda, L. A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-12-11
- Volume
- 7
- Issue
- 5
- Pages
- 5273-5288
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2213752852
- Cited by
- 88
- References
- 13
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations. https://app.cochat.ai/papers/10.18632/oncotarget.6567
- The paper
- Lorenz, S., Barøy, T., Sun, J., Nome, T., Vodák, D., Bryne, J.-C., Håkelien, A.-M., Fernandez-Cuesta, L., Möhlendick, B., Rieder, H., Szuhai, K., Zaikova, O., Ahlquist, T. C., Thomassen, G. O. S., Skotheim, R. I., Lothe, R. A., Tarpey, P. S., Campbell, P., Flanagan, A., . . . Meza-Zepeda, L. A. (2016). Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations. Oncotarget. https://doi.org/10.18632/oncotarget.6567
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.